MX2019015286A - Inmunogenos peptidicos del extremo c-terminal de proteinas alfa-sinucleinas y formulaciones de las mismas para el tratamiento de sinucleinopatias. - Google Patents
Inmunogenos peptidicos del extremo c-terminal de proteinas alfa-sinucleinas y formulaciones de las mismas para el tratamiento de sinucleinopatias.Info
- Publication number
- MX2019015286A MX2019015286A MX2019015286A MX2019015286A MX2019015286A MX 2019015286 A MX2019015286 A MX 2019015286A MX 2019015286 A MX2019015286 A MX 2019015286A MX 2019015286 A MX2019015286 A MX 2019015286A MX 2019015286 A MX2019015286 A MX 2019015286A
- Authority
- MX
- Mexico
- Prior art keywords
- syn
- constructs
- alpha
- peptide immunogen
- synucleinopathies
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 3
- 208000032859 Synucleinopathies Diseases 0.000 title abstract 2
- 102000003802 alpha-Synuclein Human genes 0.000 title abstract 2
- 108090000185 alpha-Synuclein Proteins 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title 1
- 230000002163 immunogen Effects 0.000 abstract 4
- 210000003719 b-lymphocyte Anatomy 0.000 abstract 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 abstract 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 1
- 239000004471 Glycine Substances 0.000 abstract 1
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 229960001230 asparagine Drugs 0.000 abstract 1
- 235000009582 asparagine Nutrition 0.000 abstract 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 abstract 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 abstract 1
- 210000002443 helper t lymphocyte Anatomy 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 239000000178 monomer Substances 0.000 abstract 1
- 125000006850 spacer group Chemical group 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/563—Immunoassay; Biospecific binding assay; Materials therefor involving antibody fragments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
Abstract
La presente divulgación está dirigida a constructos de inmunógenos peptídicos de alfa-sinucleína (a-Syn), composiciones que contiene los constructos, anticuerpos provocados mediante los constructos, y métodos para hacer y utilizar los constructos y composiciones de los mismos. Los constructos de inmunógenos peptídicos de a-Syn divulgados contienen un epítopo de linfocito B a partir de una a-Syn enlazada a un epítopo de linfocito T cooperador (Th) directamente o a través de un espaciador heterólogo opcional. La porción del epítopo de linfocito B de los constructos de inmunógenos peptídicos contiene aproximadamente 10 hasta aproximadamente 25 residuos de aminoácido de una a-Syn, correspondiendo a la secuencia de aproximadamente Glicina en la posición 111 (G111) hasta aproximadamente la Asparagina en la posición 135 (D135) de una a-Syn de longitud completa. Los constructos de inmunógenos peptídicos de a-Syn estimulan la generación de anticuerpos altamente específicos que son de reactividad cruzada con la lámina-ß de a-Syn como monómeros, oligómeros y fibrillas, pero diferentes a la hélice-a natural de a-Syn, ofreciendo respuestas inmunes terapéuticas a anfitriones en resigo de sinucleinopatías.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762521287P | 2017-06-16 | 2017-06-16 | |
| PCT/US2018/037938 WO2018232369A1 (en) | 2017-06-16 | 2018-06-15 | Peptide immunogens from the c-terminal end of alpha-synuclein protein and formulations thereof for treatment of synucleinopathies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019015286A true MX2019015286A (es) | 2020-08-17 |
Family
ID=64659951
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019015286A MX2019015286A (es) | 2017-06-16 | 2018-06-15 | Inmunogenos peptidicos del extremo c-terminal de proteinas alfa-sinucleinas y formulaciones de las mismas para el tratamiento de sinucleinopatias. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20210138049A1 (es) |
| EP (1) | EP3638298A4 (es) |
| JP (2) | JP2021508672A (es) |
| KR (2) | KR20240150813A (es) |
| AU (1) | AU2018283510A1 (es) |
| BR (1) | BR112019026707A2 (es) |
| CA (1) | CA3067231A1 (es) |
| MX (1) | MX2019015286A (es) |
| SG (1) | SG11201912195TA (es) |
| WO (1) | WO2018232369A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3583124A1 (en) | 2017-02-17 | 2019-12-25 | Bristol-Myers Squibb Company | Antibodies to alpha-synuclein and uses thereof |
| WO2019084488A1 (en) * | 2017-10-27 | 2019-05-02 | United Neuroscience | IMMUNOGENIC CONSTRUCTS OF PEPTIDE TAU |
| BR112021012668A2 (pt) * | 2018-12-28 | 2021-12-28 | United Biomedical Inc | Imunógenos de peptídeos que possuem como alvo interleucina 6 (il-6) e formulações dos mesmos para imunoterapia de doenças impactadas pela desregulação de il-6 |
| KR20230044524A (ko) * | 2020-08-04 | 2023-04-04 | 에이씨 이뮨 에스에이 | 면역원성 화합물 |
| CA3192429A1 (en) * | 2020-09-17 | 2022-03-24 | Robin Barbour | Alpha-synuclein vaccine for the treatment of synucleinopathies |
| KR102505164B1 (ko) * | 2020-09-29 | 2023-02-28 | 서울대학교산학협력단 | 신경퇴행성 질환의 예방 또는 치료용 펩타이드 및 이를 포함하는 약학 조성물 |
| TW202306966A (zh) * | 2021-06-18 | 2023-02-16 | 日商住友製藥股份有限公司 | 人類α突觸核蛋白之抗原決定位肽及包含該肽之醫藥組合物 |
| CA3230300A1 (en) * | 2021-09-01 | 2023-03-09 | Jean-Cosme DODART | Methods for the prevention and treatment of synucleinopathies |
| WO2023161527A1 (en) | 2022-02-28 | 2023-08-31 | Tridem Bioscience Gmbh & Co Kg | A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6906169B2 (en) * | 2001-05-25 | 2005-06-14 | United Biomedical, Inc. | Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide |
| US7358331B2 (en) * | 2003-05-19 | 2008-04-15 | Elan Pharmaceuticals, Inc. | Truncated fragments of alpha-synuclein in Lewy body disease |
| US20120142902A1 (en) * | 2007-02-23 | 2012-06-07 | The Regents Of The University Of California | Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease |
| BRPI0923157B1 (pt) * | 2008-12-19 | 2021-12-28 | University Of Zürich | Anticorpos anti-alfa-sinucleína e seus fragmentos, seus usos e método de preparação, composição compreendendo-os, bem como kit e métodos para o diagnóstico e monitoramento de uma doença sinucleinopática |
| US20150139937A1 (en) * | 2012-05-18 | 2015-05-21 | Board Of Regents Of The University Of Nebraska | Methods and Compositions For Inhibiting Diseases of the Central Nervous System |
| AU2013305848B2 (en) * | 2012-08-21 | 2020-10-15 | Institute For Molecular Medicine, Inc. | Compositions and methods related to diseases associated with deposits of amyloid, Tau, and alpha-synuclein |
| US9102752B2 (en) * | 2013-03-15 | 2015-08-11 | United Biomedical, Inc. | Peptide vaccine for prevention and immunotherapy of dementia of the Alzheimer's type |
| WO2015157117A2 (en) * | 2014-04-09 | 2015-10-15 | The Trustees Of Columbia University In The City Of New York | Use of leukocytes and novel biomarkers in the diagnosis, confirmation, and treatment of a neurological disorder |
| WO2015179867A1 (en) * | 2014-05-23 | 2015-11-26 | University Of South Florida | Methods, antibodies, and vaccines utilizing epitopes of alpha synuclein for treatment of parkinson's disease |
-
2018
- 2018-06-15 MX MX2019015286A patent/MX2019015286A/es unknown
- 2018-06-15 KR KR1020247032769A patent/KR20240150813A/ko active Search and Examination
- 2018-06-15 EP EP18816482.6A patent/EP3638298A4/en active Pending
- 2018-06-15 US US16/623,205 patent/US20210138049A1/en active Pending
- 2018-06-15 AU AU2018283510A patent/AU2018283510A1/en active Pending
- 2018-06-15 CA CA3067231A patent/CA3067231A1/en active Pending
- 2018-06-15 BR BR112019026707-7A patent/BR112019026707A2/pt unknown
- 2018-06-15 JP JP2020519016A patent/JP2021508672A/ja active Pending
- 2018-06-15 WO PCT/US2018/037938 patent/WO2018232369A1/en unknown
- 2018-06-15 SG SG11201912195TA patent/SG11201912195TA/en unknown
- 2018-06-15 KR KR1020207001265A patent/KR20200054938A/ko not_active Application Discontinuation
-
2023
- 2023-03-15 JP JP2023040466A patent/JP2023082018A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018283510A1 (en) | 2020-01-16 |
| BR112019026707A2 (pt) | 2020-06-30 |
| RU2020101121A (ru) | 2021-07-16 |
| US20210138049A1 (en) | 2021-05-13 |
| KR20200054938A (ko) | 2020-05-20 |
| EP3638298A1 (en) | 2020-04-22 |
| KR20240150813A (ko) | 2024-10-16 |
| JP2021508672A (ja) | 2021-03-11 |
| JP2023082018A (ja) | 2023-06-13 |
| RU2020101121A3 (es) | 2021-10-15 |
| EP3638298A4 (en) | 2021-05-05 |
| CA3067231A1 (en) | 2018-12-20 |
| SG11201912195TA (en) | 2020-01-30 |
| WO2018232369A1 (en) | 2018-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019015286A (es) | Inmunogenos peptidicos del extremo c-terminal de proteinas alfa-sinucleinas y formulaciones de las mismas para el tratamiento de sinucleinopatias. | |
| MX2015013235A (es) | Vacuna peptidica para prevencion e inmunoterapia de la demencia tipo alzheimer. | |
| MX2019006349A (es) | Proteinas recombinantes rsv f de prefusion nuevas y usos de las mismas. | |
| ME00183B (me) | Novi postupak za deregulaciju amiloida | |
| EA201892250A1 (ru) | Вакцина против rsv | |
| NZ618391A (en) | Antigenic tau peptides and uses thereof | |
| CY1110051T1 (el) | Πεπτιδια που σχετιζονται με ογκους τα οποια συνδεονται αδιακριτα σε μορια του αντιγονου ανθρωπινων λευκοκυτταρων (hla) ταξης ii | |
| EA200900795A1 (ru) | Вакцина | |
| HRP20190752T1 (hr) | Novo protutijelo protiv ljudskog receptora tslp | |
| EA200800676A1 (ru) | Опухолеассоциированные пептиды, связывающиеся с молекулами человеческого лейкоцитарного антигена (hla) i или ii класса, и относящаяся к ним противораковая вакцина | |
| MX2015012527A (es) | Polipeptidos de union hiperglicosilados. | |
| FI3452507T3 (fi) | Tau-immuunihoito | |
| BR112017009177A2 (pt) | vacinas terapêuticas contra hpv16 | |
| ATE421533T1 (de) | Immunogene t-helfer epitope von menschlichen tumorantigenen und deren verwendung in immunotherapeutischen methoden | |
| WO2008124646A3 (en) | Use of amyloid proteins as vaccine scaffolds | |
| AR079114A1 (es) | Proteinas de enlace de antigenos anti-orai1 y usos de las mismas | |
| EA201170217A1 (ru) | Гибридные полипептидные антигены респираторно-синцитиального вируса | |
| RU2017132689A (ru) | СЛИТАЯ С Fc α-ЦЕПЬ ВЫСОКОАФФИННОГО РЕЦЕПТОРА IgE | |
| MX2019002178A (es) | Peptidos de fusion con antigenos enlazados a fragmentos cortos de cadena invariante (cd74). | |
| RU2015154795A (ru) | Иммуногенная композиция, ее включающая вакцина, набор для приготовления вышеуказанной композиции и способ лечения заболеваний, связанных с патологией секреции гастрина | |
| EA201690056A8 (ru) | ИСКУССТВЕННЫЕ БЕЛКИ, СВЯЗЫВАЮЩИЕ ФАКТОР Н (fHbp), И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| ZA202203778B (en) | Method for increasing lymphocyte count by using il-7 fusion protein in tumors | |
| HRP20220064T1 (hr) | Zglobno modificirani fragmenti protutijela i postupci za pripravu | |
| RU2018117921A (ru) | Получение in vivo n-дегликозилированных рекомбинантных белков посредством совместной экспрессии с endo h | |
| WO2013171661A3 (en) | Adjuvant formulations and methods |